Genelux Corporation (GNLX)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Developing Oncolytic Immunotherapies	8.00K	8.00K	170.00K	11.07M	-
Developing Oncolytic Immunotherapies Growth	0%	-95.29%	-98.46%	-	-
Total	8.00K	8.00K	170.00K	11.07M	-
Total Growth	0%	-95.29%	-98.46%	-	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
United States	8.00K	8.00K	170.00K	11.07M	-
United States Growth	0%	-95.29%	-98.46%	-	-
Total	8.00K	8.00K	170.00K	11.07M	-
Total Growth	0%	-95.29%	-98.46%	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 19, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 13, 2026

Data Sources Report a data error